IBDEI36L ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,50793,1,4,0)
 ;;=4^D51.1
 ;;^UTILITY(U,$J,358.3,50793,2)
 ;;=^5002285
 ;;^UTILITY(U,$J,358.3,50794,0)
 ;;=D51.9^^193^2497^197
 ;;^UTILITY(U,$J,358.3,50794,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50794,1,3,0)
 ;;=3^Vitamin B12 Deficiency Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,50794,1,4,0)
 ;;=4^D51.9
 ;;^UTILITY(U,$J,358.3,50794,2)
 ;;=^5002289
 ;;^UTILITY(U,$J,358.3,50795,0)
 ;;=D68.0^^193^2497^199
 ;;^UTILITY(U,$J,358.3,50795,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50795,1,3,0)
 ;;=3^Von Willebrand's Disease
 ;;^UTILITY(U,$J,358.3,50795,1,4,0)
 ;;=4^D68.0
 ;;^UTILITY(U,$J,358.3,50795,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,50796,0)
 ;;=C88.0^^193^2497^200
 ;;^UTILITY(U,$J,358.3,50796,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50796,1,3,0)
 ;;=3^Waldenstrom Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,50796,1,4,0)
 ;;=4^C88.0
 ;;^UTILITY(U,$J,358.3,50796,2)
 ;;=^5001748
 ;;^UTILITY(U,$J,358.3,50797,0)
 ;;=C91.02^^193^2497^3
 ;;^UTILITY(U,$J,358.3,50797,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50797,1,3,0)
 ;;=3^Acute Lymphoblastic Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,50797,1,4,0)
 ;;=4^C91.02
 ;;^UTILITY(U,$J,358.3,50797,2)
 ;;=^5001764
 ;;^UTILITY(U,$J,358.3,50798,0)
 ;;=C92.02^^193^2497^6
 ;;^UTILITY(U,$J,358.3,50798,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50798,1,3,0)
 ;;=3^Acute Myeloblastic Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,50798,1,4,0)
 ;;=4^C92.02
 ;;^UTILITY(U,$J,358.3,50798,2)
 ;;=^5001791
 ;;^UTILITY(U,$J,358.3,50799,0)
 ;;=D09.3^^193^2497^46
 ;;^UTILITY(U,$J,358.3,50799,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50799,1,3,0)
 ;;=3^Carcinoma in Situ of Thyroid/Oth Endocrine Glands
 ;;^UTILITY(U,$J,358.3,50799,1,4,0)
 ;;=4^D09.3
 ;;^UTILITY(U,$J,358.3,50799,2)
 ;;=^5001955
 ;;^UTILITY(U,$J,358.3,50800,0)
 ;;=C22.0^^193^2497^87
 ;;^UTILITY(U,$J,358.3,50800,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50800,1,3,0)
 ;;=3^Hepatocellular Carcinoma
 ;;^UTILITY(U,$J,358.3,50800,1,4,0)
 ;;=4^C22.0
 ;;^UTILITY(U,$J,358.3,50800,2)
 ;;=^5000933
 ;;^UTILITY(U,$J,358.3,50801,0)
 ;;=C24.9^^193^2497^114
 ;;^UTILITY(U,$J,358.3,50801,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50801,1,3,0)
 ;;=3^Malig Neop Biliary Tract,Unspec
 ;;^UTILITY(U,$J,358.3,50801,1,4,0)
 ;;=4^C24.9
 ;;^UTILITY(U,$J,358.3,50801,2)
 ;;=^5000942
 ;;^UTILITY(U,$J,358.3,50802,0)
 ;;=C50.922^^193^2497^138
 ;;^UTILITY(U,$J,358.3,50802,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50802,1,3,0)
 ;;=3^Malig Neop Left Male Breast,Unspec Site
 ;;^UTILITY(U,$J,358.3,50802,1,4,0)
 ;;=4^C50.922
 ;;^UTILITY(U,$J,358.3,50802,2)
 ;;=^5133340
 ;;^UTILITY(U,$J,358.3,50803,0)
 ;;=C34.91^^193^2497^156
 ;;^UTILITY(U,$J,358.3,50803,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50803,1,3,0)
 ;;=3^Malig Neop Right Bronchus/Lung,Unspec Part
 ;;^UTILITY(U,$J,358.3,50803,1,4,0)
 ;;=4^C34.91
 ;;^UTILITY(U,$J,358.3,50803,2)
 ;;=^5000967
 ;;^UTILITY(U,$J,358.3,50804,0)
 ;;=C50.921^^193^2497^160
 ;;^UTILITY(U,$J,358.3,50804,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50804,1,3,0)
 ;;=3^Malig Neop Right Male Breast,Unspec Site
 ;;^UTILITY(U,$J,358.3,50804,1,4,0)
 ;;=4^C50.921
 ;;^UTILITY(U,$J,358.3,50804,2)
 ;;=^5001198
 ;;^UTILITY(U,$J,358.3,50805,0)
 ;;=C90.02^^193^2497^172
 ;;^UTILITY(U,$J,358.3,50805,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50805,1,3,0)
 ;;=3^Multiple Myeloma,In Relapse
 ;;^UTILITY(U,$J,358.3,50805,1,4,0)
 ;;=4^C90.02
